	Area of Research	Phase 1	Phase 2	Phase 3	Post-Approval Research
MULTIPLE MYELOMA (MM)					
REVLIMID® (lenalidomide)	Relapsed/refractory	■	■	■	■
	Newly diagnosed	■	■	■	■
	Maintenance	■	■	■	■
POMALYST®/IMNOVID® (US/EU) (pomalidomide)	Relapsed/refractory	■	■	■	■
THALOMID®/Thalidomide Celgene® (US/EU) (thalidomide)	Newly diagnosed	■	■	■	■
bb2121 (BCMA CAR T)[a]	Relapsed/refractory	■	■	■	
bb21217 (BCMA CAR T)[a]	Relapsed/refractory	■			
JCARH125 (BCMA CAR T)	Relapsed/refractory	■			
Iberdomide (CC-220)	Relapsed/refractory	■			
CC-92480 (CELMoD)	Relapsed/refractory	■			
CC-93269 (BCMA TCE)	Relapsed/refractory	■			
MYELODYSPLASTIC SYNDROMES (MDS)					
VIDAZA® (azacitidine for injection)		■	■	■	■
REVLIMID® (lenalidomide)	Deletion 5q	■	■	■	■
CC-486 (DNMT inhibitor)	Lower-risk	■	■	■	
	Post hypomethylating agent (HMA) failure	■	■		
Luspatercept (ACE-536)[b]	First-line	■	■	■	
	Second-line	■	■		
ACUTE MYELOID LEUKEMIA (AML)					
VIDAZA® (azacitidine for injection)	AML (20%-30% blasts) (EU)	■	■	■	■
	AML (>30% blasts) (EU)	■	■	■	■
CC-486 (DNMT inhibitor)	Post-induction AML maintenance	■	■	■	
IDHIFA® (enasidenib)[c]	Relapsed/refractory IDH2 mutation (US)	■	■	■	■
	Newly diagnosed AML with an IDH2 mutation	■			
CC-90009 (CELMoD)	Relapsed/refractory	■			
GEM333 (CD3XCD33 Bispecific Antibody)[d]		■			
CC-95775 (BET inhibitor)		■			

[a]In collaboration with bluebird bio, Inc. bluebirdbio [b]In collaboration with Acceleron Pharma, Inc. ACCELERON
[c]In collaboration with Agios Pharmaceuticals, Inc. agios [d]In collaboration with GEMoaB Monoclonals GmbH. gemoab

REVLIMID®, POMALYST®, IMNOVID®, THALOMID®, Thalidomide Celgene®, VIDAZA®, and IDHIFA® are registered trademarks of Celgene Corporation.

Celgene

For information on approved uses, please refer to approved product labeling. Post-approval research includes Celgene-sponsored and Celgene-supported studies.

The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established. There is no guarantee that investigational agents or investigational uses will receive health authority approval or become commercially available in any country.

© 2019 Celgene Corporation 04/19

	Area of Research	Phase 1	Phase 2	Phase 3	Post-Approval Research
LYMPHOMA					
REVLIMID® (lenalidomide)	Mantle cell lymphoma: Relapsed/refractory				
	Diffuse large B-cell lymphoma (ABC subtype): First-line				
	Follicular/marginal zone lymphoma: Relapsed/refractory				
ISTODAX® (romidepsin) for injection	Cutaneous T-cell lymphoma (US)[a]				
	Peripheral T-cell lymphoma: Relapsed/refractory[a]				
	Peripheral T-cell lymphoma: First-line				
liso-cel[b]; CD-19 (CAR T)	Aggressive large B-cell lymphoma: Relapsed/refractory				
CC-486 (DNMT inhibitor)	Angioimmunoblastic T-cell lymphoma				
CC-90002 (Anti-CD47)	Non-Hodgkin lymphoma				
Avadomide (CC-122)	Diffuse large B-cell lymphoma				
CC-90010 (BET inhibitor)	Non-Hodgkin lymphoma				
CC-95775 (BET inhibitor)	Non-Hodgkin lymphoma				
CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)					
liso-cel[b]; CD-19 (CAR T)					
BETA-THALASSEMIA					
Luspatercept (ACE-536)[c]	Transfusion-dependent				
	Non-transfusion-dependent				
MYELOFIBROSIS (MF)					
Fedratinib					
Luspatercept (ACE-536)[c]	MF anemia				

[a]Filing for regulatory approval based on pivotal phase 2 data. [b]Lisocabtagene maraleucel.

[c]In collaboration with Acceleron Pharma, Inc. ACCELERON

REVLIMID® and ISTODAX® are registered trademarks of Celgene Corporation.

Celgene

For information on approved uses, please refer to approved product labeling. Post-approval research includes Celgene-sponsored and Celgene-supported studies.

The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established. There is no guarantee that investigational agents or investigational uses will receive health authority approval or become commercially available in any country.

© 2019 Celgene Corporation 04/19

	Area of Research	Phase 1	Phase 2	Phase 3	Post-Approval Research
SOLID TUMORS					
ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) (US)/ (paclitaxel formulated as albumin-bound nanoparticles) (EU)	Breast: Metastatic				
	Non-small cell lung: Advanced (First-line)				
	Pancreatic: Metastatic (First-line)				
	Pancreatic: Adjuvant				
	Gastric: Metastatic (Japan)[a]				
Marizomib	Glioblastoma				
Tislelizumab (BGB-A317)[b]	Non-small cell lung cancer				
CC-90011					
CC-90010 (BET inhibitor)					
CC-95251					
INFLAMMATION & IMMUNOLOGY					
OTEZLA® (apremilast)	Psoriatic arthritis				
	Psoriasis (Mild to Moderate)				
	Psoriasis (Moderate to Severe)				
	Psoriasis (Pediatric)				
	Behçet's disease				
	Scalp psoriasis				
	Genital psoriasis				
Ozanimod	Relapsing multiple sclerosis				
	Ulcerative colitis				
	Crohn's disease				
CC-93538	Eosinophilic esophagitis				
Iberdomide (CC-220)	Systemic lupus erythematosus				
CC-90001	Idiopathic pulmonary fibrosis				
CC-90006	Psoriasis				

[a]Trial conducted by licensee partner, Taiho Pharmaceuticals Co. Ltd. [b]In collaboration with BeiGene, Ltd. BeiGene

ABRAXANE® and OTEZLA® are registered trademarks of Celgene Corporation.

Celgene

For information on approved uses, please refer to approved product labeling. Post-approval research includes Celgene-sponsored and Celgene-supported studies.

The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established. There is no guarantee that investigational agents or investigational uses will receive health authority approval or become commercially available in any country.

© 2019 Celgene Corporation 04/19